GOSS Stock Recent News
GOSS LATEST HEADLINES
Penny stocks are an interesting category. While they have the potential to produce significant long-run gains, you should never bet money on these stocks that you can't afford to lose.
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and systemic absorption issues, unlike seralutinib, which targets key disease pathways effectively. Tyvaso DPI's success in PH-ILD highlights the unmet need, with Gossamer planning a Phase 3 trial for seralutinib in mid-2025.
Gossamer Bio (GOSS) came out with quarterly earnings of $0.22 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to loss of $0.45 per share a year ago.
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Do you have any penny stocks in your portfolio? If you don't, you might want to consider it with any speculative money sitting on the sidelines.
Gossamer Bio said on Monday it will collaborate with Chiesi Group to develop and commercialize its drug seralutinib in multiple indications related to blood pressure conditions.
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
Practically by default, your typical financial advisor will steer you clear of micro-cap stock surprises in favor of large-capitalization enterprises. Yes, the blue chips are reliable and dependable but this underlying predictability often comes at a cost: usually, you're not going to get rich off of them.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Sera.